Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules
Open Access
- 2 September 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9), e0237492
- https://doi.org/10.1371/journal.pone.0237492
Abstract
Oncimmune's EarlyCDT®-Lung is a simple ELISA blood test that measures seven lung cancer specific autoantibodies and is used in the assessment of malignancy risk in patients with indeterminate pulmonary nodules (IPNs). The objective of this study was to examine the cost-effectiveness of EarlyCDT-Lung in the diagnosis of lung cancer amongst patients with IPNs in addition to CT surveillance, compared to CT surveillance alone which is the current recommendation by the British Thoracic Society guidelines. A model consisting of a combination of a decision tree and Markov model was developed using the outcome measure of the quality adjusted life year (QALY). A life-time time horizon was adopted. The model was parameterized using a range of secondary sources. At £70 per test, EarlyCDT-Lung and CT surveillance was found to be cost-effective compared to CT surveillance alone with an incremental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy parameters used. It was also found that EarlyCDT-Lung can be priced up to £1,177 and still be cost-effective based on cost-effectiveness acceptance threshold of £20,000 / QALY. Further research to resolve parameter uncertainty, was not found to be of value. The results here demonstrate that at £70 per test the EarlyCDT-Lung will have a positive impact on patient outcomes and coupled with CT surveillance is a cost-effective approach to the management of patients with IPNs. The conclusions drawn from this analysis are robust to realistic variation in the parameters used in the model.Funding Information
- SBRI Healthcare NHS England
This publication has 11 references indexed in Scilit:
- Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countriesThe European Journal of Health Economics, 2018
- Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule EvaluationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2017
- Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT-Lung Diagnostic Performance and Its Application to Indeterminate Pulmonary NodulesJournal of Cancer Therapy, 2017
- The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancerHealth Technology Assessment, 2016
- British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICEThorax, 2015
- Cost-Effectiveness of CT Screening in the National Lung Screening TrialThe New England Journal of Medicine, 2014
- Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis SampleMedical Decision Making, 2013
- Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluationHealth Technology Assessment, 2012
- Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary NodulesAnnals of Internal Medicine, 2003
- Handling Uncertainty in Cost-Effectiveness ModelsPharmacoEconomics, 2000